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Radiation can cause damage to the inner ear, from a simple 
hearing loss all the way to profound deafness. Amifostine 
is a cytoprotective substance extensively used during radio-
chemotherapy for malignant tumors. Aim: the objective of 
the present investigation was to establish the antioxidant 
and radioprotective effects of amifostine on the organ of 
Corti of albino guinea pigs irradiated in the head and neck 
region. Materials and Methods: An experimental study 
conducted on four groups of guinea pigs were used; One 
group received only amifostine, one group was submitted 
to a single dose of 350 cGy and the other two were similarly 
irradiated but received amifostine doses of 100 or 200 mg/kg. 
All animals were slaughtered 30 days after the experiment, 
their bullae were removed and the damaged outer hair cells 
were counted. Result: The extent of injury was lower in the 
outer hair cells of the two groups treated with amifostine 
compared to the group that was only irradiated. There was 
no difference between the group treated with 100 and 200 
mg/kg of amifostine. The group that received only amifostine 
had no cochlear damage. Conclusion: Amifostine is an 
effective cytoprotective substance in the Organ of Corti of 
irradiated guinea pigs.
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INTRODUCTION
Radiotherapy is one of the most used treatment 
modalities against malignant tumors located in the head 
and neck region. Its mechanism of action on cancer cells 
is based on de-structuring its nucleotide sequence, thus 
changing cell molecules, proteins and DNA - affecting cell 
metabolism and its division mechanism, thus preventing 
tumor growth.
One of the major drawbacks of head and neck ra-
diotherapy is the very fact that the temporal bone and inner 
ear structures are within the radiation field of most tumors, 
as it happens with rhinopharynx tumors. In this case, the 
hearing organs are inevitably involved in the irradiation 
field and the patient may develop hearing loss of different 
degrees, which can even cause profound hearing loss1,2.
As radiation reaches the vestibulo-cochlear organ, 
hearing and balance disorders may ensue3. Among them, 
sensorineural hearing loss is the most common complica-
tion and it is more commonly associated with the loss of 
outer hair cells in the organ of Corti4.
Many efforts have been made attempting to mini-
mize or neutralize the effects of irradiation to the inner 
ear; however, the greatest progresses have been seen only 
regarding the development of new techniques, radiation 
emission equipment and proton-type power sources, whi-
ch have reduced the effects of radiation on the hearing 
organ5,6.
There are many studies in the literature regarding 
cytoprotective drugs against the deleterious effects of ra-
diation on normal tissue. Nonetheless, there are almost no 
studies associated with the action of radiation protection 
drugs specifically in the inner ear.
One of the major drugs considered for its selective 
cytoprotective effect and low toxicity against the harmful 
effects of radiotherapy is amifostine.
The goal of the present investigation was to check 
whether or not amifostine, administered in the doses of 
100 e 200mg/Kg, intraperitoneally, prior to the irradiation 
dose of 350cGy to the inner ear has any cytoprotective 
function and, if this protection is significant and selective, 
prioritizing certain cochlear turns or hair cell groups inside 
a given cochlear turn.
MATERIALS AND METHODS
The present study involved 51 male albino guinea 
pigs weighing between 300g and 450g which passed the 
positive Preyer reflex hearing screening7 test and had dis-
tortion products otoacoustic emissions, prior to the study 
onset, carried out in a System Otodynamics ILO 92 CAE 
device. The triggering stimulus was of 70dB SPL both for 
F1 and F2, following the 2F1-F2 frequency relation with 
F1:F2 ratio = 1.22 and resolution of two points per octave.
The animals were broken down into four distinctive 
groups, which were: Amifostine group - made up of four 
animals, which received amifostine alone in the dose of 
200mg/Kg, intraperitoneally (IP), and served as a negative 
control for the experiment, since there is no report of oto-
toxic effect of this drug in the literature; Irradiation Group 
(Irr) - made up of 11 guinea pigs which received only 
irradiation to the head and neck at the dose of 350cGy, 
symmetrically in each ear; Amifostine 100mg+Irradiation 
(Irr+100mg) Group - made up of 18 animals which received 
amifostine at the dose of 100mg/kg, IP, 30 minutes before 
the irradiation of 350cGy; Amifostine 200mg+Irradiation 
(Irr+200mg) Group - made up of 18 animals which received 
200mg/kg, IP, 30 minutes prior to the irradiation of 350cGy. 
All the groups remained in the experimental surgery lab, 
complying with the food and housing demands established 
by the Animal Experimentation Ethics Committee, protocol 
# 043/2005 approved on March 27, 2006, and the animals 
were slaughtered 30 days after the experiment.
The method used to compare the amount of damage 
to the organ of Corti was to count the outer hair cells which 
were missing in the three rows of cochlear turns: E1, E2, 
and E3. The parameter used to classify the lesion was the 
total lack of hairs, in other words, the complete loss of 
filamentary projection of the hairs on the cuticular plate. 
The site chosen for cell count was the middle segment of 
each turn, obtaining the largest possible number of cells 
within a photographic microscopic field at a magnifica-
tion of 350 to 700 times. All the turns were photographed 
and the negatives were developed for later analysis. The 
numbers resulting from such cell count were turned into 
fractions of the total number of cells missing, divided by 
the total population of cells from that photographic field 
analyzed.
In order to compare the study groups, we held three 
analyses: the first compared the percentage of damaged 
cells among the groups (Irr, Irr+100mg e Irr+200mg) 
considering the percentage of damaged outer hair cells 
summation on the three turns (E1, E2 and E3) from each 
group; the second compared the percentage of damaged 
outer hair cells in each turn (E1, E2 and E3) among the 
three groups investigated; the third compared the percen-
tage of damaged outer hair cells in each row (F1, F2 and 
F3) among the three groups.
The results were then submitted to statistical analysis 
using the Statistical Package for Social Sciences - (SPSS) 
software. In comparing the values among the three groups 
we used the Kruskal-Wallis non-parametric test with post 
hoc test from Dunn when we noticed the existence of 
significant difference. For this statistical analysis we used 
p ≤ 0.05 as level of significance.
RESULTS
The present paper involved a total of 51 animals, 
and there were seven deaths. Of these, two happened in 
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the Irr+200mg group, four in the Irr+100mg group, and 
one in the amifostine group. All the deaths happened 
because of a diarrhea, very likely of viral origin. From the 
44 remaining animals we had 88 cochleas, and at the end 
of the study we had only 84 -three cochleas were taken 
off the study because the animals had signs of middle ear 
inflammation/infection and one cochlea was lost because 
it was damaged during the dissection.
Since there was no damage in the group which 
received amifostine alone - which matches literature fin-
dings, comparative studies were carried out only among 
the other study groups.
Comparing the percentage of the total number of 
OHCs among the groups
Comparing the total number of OHC damaged in 
each study group it was seen that, in the Irr group the 
percentage of OHC damage was significantly higher than 
that in groups Irr+100mg and Irr+200mg, which were 
equivalent (Figure 1).
cant when the total number of damaged cells in this turn 
were compared to the other two groups which received 
amifostine prior to irradiation. Among the groups which 
received amifostine there was no statistically significant 
difference (Figs. 4 and 5).
Turn 3
On the third turn, comparing to E2, there was a hi-
gher damage trend in the three groups. Here also, groups 
Irr+100mg and Irr+200mg showed significantly lower 
values compared to the irradiated group alone. The two 
groups which used amifostine were equivalent and did 
not show significant differences (Figs 6 and 7).
Comparing the percentage of damaged outer hair 
cells in each row (F1, F2 and F3) among the groups.
Turn 1 - Rows 1, 2 and 3
In comparing the rows in the first turn, there was no 
significant difference among the percentages of damaged 
OHCs in the study groups (Fig. 8).
Figure 1. Percentage of damaged OHCs in each group.
Comparing the percentage of damaged outer hair 
cells in each cochlear turn (E1, E2 and E3) among the 
groups
Turn 1
In cochlear turn 1 we almost did not see any damage 
in any of the groups studied and, when they did happen, 
it was in an isolate and inconstant way. Applying the sta-
tistic test, there was no significant difference among the 
groups which received amifostine (100mg/kg and 200mg/
kg) before the irradiation and those which were irradiated 
alone in the dose of 350cGy (Figs 2 and 3).
Turn 2
In the second turn, we see an increase in blank spots 
in outer hair cell rows, mainly in the group which did not 
use amifostine prior to the irradiation. The greater level 
of damage suffered by this group was statistically signifi-
Figure 2. Percentage of damaged OHCs in the first turn.
Figure 3. Lesion-free segment of turn 1 in the Irr group.
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Turn 2 - Rows 1, 2 and 3
In comparing the percentages of damaged OHCs in 
the isolated rows in the groups, we observed that, despite 
the higher damage mean values in the second (F2) and 
third (F3) rows, it was only in the first row (F1) that we 
noticed a significant difference by the Dunn post hoc test, 
in which the group that was only irradiated (Irr) showed 
significantly higher damage values than groups Irr+ 100mg 
and Irr+200mg - which were equivalent (Figure 9).
Turn 3 - Rows 1, 2 and 3
Comparing the percentages of damaged OHCs 
among the isolate rows in this turn we noticed a trend 
towards higher damaged mean values in the second (F2) 
and third (F3) rows, repeating what happened in row 2. 
However, only the third row (F3) had significant lesion 
Figure 4. Percentage of damaged OHCs in turn 2.
Figure 5. Turn 2 in the Irr+200mg group showing OHC preservation.
Figure 6. Percentage of damaged OHC in turn 3.
Figure 7. Turn 3 from the Irr+200mg group with OHC preservation.
Figure 8. Lesion-free turn 1 of the Irr+200mg group.
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increase in the group that was only irradiated, compared 
to the other two groups which received amifostine in the 
doses of 100mg and 200mg/kg, which were equivalent 
(Fig. 10).
As to the types of hearing loss induced by radiothe-
rapy, it is known that they can be air-conduction-related, 
sensorineural and mixed. Sensorineural hearing loss is, 
without doubts, the most frequent and, according to some 
authors, it can happen in up to 75% of the patients irradia-
ted in the temporal bone region and it usually develops 
through the lesion to the organ of Corti and less frequen-
tly through an 8th cranial never degeneration, given that 
central nervous system structures have a greater resistance 
towards this treatment mode8.
As to the dose which is damaging to the organ of 
Corti, the higher the irradiation dose to the inner ear, the 
greater is the likelihood of an auditory damage9. In general, 
the total radiation dose necessary to damage the auditory 
system varies between 3,000 and 6,000 cGy, when divided 
in small fractions10-12. In our study, the dose necessary to 
cause immediate damage to the hair cells was 350cGy, 
applied in a single dose. Such dose was established based 
on a pilot study previously carried out in our Department, 
given that there was no information in the literature about 
the average damaging dose to the organ of Corti of albino 
guinea pigs.
Post-radiation hearing loss can be immediate or 
late2. The immediate complication results from the direct 
cell injury caused by the radiation on the structures of the 
organ of Corti and the stria vascularis. Now, the late effects 
caused by the indirect action of radiation on the inner ear 
vessels, generating obliterating endarteritis process, which 
progressively interrupts blood supply to vital structures of 
the cochlea neuroepithelium and the 8th cranial nerve13-15.
With reference to the frequency range most affected, 
the low and middle frequencies are rarely affected. The 
high tones are the ones most affected in the frequency 
range between 4,000 and 8,000Hz4,15. Our findings point to 
the lesion happening preferably on the second and third 
turns, preserving the first turn and the apical turn. Com-
paring the lesion degree between E2 and E3 we noticed 
that the lesion percentage was greater in the third turn, 
in most of the cases overcoming in two fold what had 
happened on the second turn. This selective mechanism 
for the turns and consequently for the hearing frequencies 
is very likely due to a greater oxygen consumption in the 
hair cells and stria vascularis closer to the cochlear base, 
which makes them more sensitive16.
Another data also observed was that there was a 
trend to an increase in the percentage of damaged cells on 
the second and third turns, especially on the two outermost 
rows, with preservation of the first and innermost. Such 
fact also noticed in other experimental studies involving 
radiation is very likely due to different metabolic needs 
which happens among these cell groups, already pointed 
out by some authors who detected differences both ana-
tomical and of biochemical constitution in the outer hair 
cells in different cochlear sectors4,17-19.
Figure 9. Turn 2 in the Irr group showing F2 and F3 lesion and F1 
preservation.
Figure 10. Irr group turn 3 with a large number of hair lesions in F2 
and F3.
DISCUSSION
Radiotherapy-induced hearing loss, despite a very 
relevant topic, is still not diagnosed enough today and, in 
a certain way, it is not enough appreciated and prevented 
among professionals involved with this treatment mode. 
This is partially due to the lack of knowledge regarding 
the progress of new radiotherapy techniques with greater 
ear protection potential and the recent discovery of drugs 
with radioprotective potential for normal tissue adjacent 
to the tumor, including the hearing organs.
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As to the use of ear protection drugs in radiotherapy, 
Atlas et al. (2006) were able to reduce radiation-induced 
cochlear damage to the spiral ganglion, stria vascularis, 
inner and outer hair cells in guinea pigs which were treated 
with piracetam one hour after irradiation of a 60Gy dose, 
by the mechanism of cell apoptosis inhibition20.
Amifostine is a pro-drug, which is converted by 
phosphatase alkaline in the WR-1065 active molecule. WR-
1065 interacts with free radicals donating hydrogen ions 
which bind to oxygen molecules and active metabolites of 
the antineoplastic agents21,22. This has given Amifostine the 
status of an efficient cytoprotective in the neurotoxicity, 
nephrotoxicity, blood toxicity and ototoxicity induced by 
cyclophosphamide, carboplatin and cysplatin23-25. Glover et 
al. (1984) studied the effect of amifostine in the inner ear 
of patients who received chemotherapy by cisplatin and 
noticed a reduction in the levels of hearing loss in patients 
receiving cisplatin in the dose of 150mg/m² 26. Hyppolito 
et al. (2005) compared the number of damaged outer hair 
cells and the behavior of DPOAE in guinea pigs treated 
with and without amifostine and the ones which received 
cisplatin. They concluded that the loss of outer hair cells 
was lower in the amifostine group and the otoacoustic 
emissions were present in all the animals of this group 
after using the ototoxic agent27.
In radiotherapy, amifostine protects many cell line-
ages from the effects of radiation. This drug has already 
been broadly tested and proved to be effective in the 
radioprotection of the bone marrow, reducing rates of 
blood toxicity - minimizing thrombocytopenia, anemia and 
leucopenia28,29. In head and neck tumors, it is believed that 
amifostine can reduce the radiotoxicity to salivary glands, 
esophageal mucosa and the oral cavity, minimizing the 
adverse effects of mucositis and xerostomia which subs-
tantially compromise the quality of life of post-irradiated 
patients30,31.
In our study it was clear that amifostine significan-
tly protected the Irr+100mg and Irr+200mg groups which 
received the drug intraperitoneally, 30 minutes before 
irradiating the inner ear, however there was no protection 
significant difference only by changing the dose from 
100mg/kg to 200mg/kg. Such protection was visibly ma-
rked in the rate of damaged hair cells and represented a 
reduction of up to 40% of the lesion percentage of OHCs 
in the groups that received amifostine. This reduction was 
probably due to the lesion differences which happened 
on the second and third turns which, in comparing the 
groups pointed to a percentage reduction of lesions in 
the Irr+100mg and Irr+200mg groups, when compared to 
the Irr groups. In comparing lesion percentage values in 
turn 1 between the groups, there was no significant lesion 
difference in any of the groups. This can be explained by 
the low level of lesion which happened by the radiation 
in this cochlear sector, in particular.
When the groups were compared in terms of rows, 
only the first row of E2 and the third row of E3 showed 
lover and statistically significant values of hair cell lesions 
in the groups Irr+100mg and Irr+200mg. This is, without 
doubt a true finding of this study, which must wait for new 
experiments in order to check whether or not it was a ca-
sual phenomenon or something specific for the drug used.
CONCLUSIONS
Amifostine used prior to inner ear irradiation sig-
nificantly protected the organ of Corti outer hair cells of 
guinea pigs irradiated in the regions of the head and neck 
by Cobalt 60, at the dose of 350cGy and it significantly 
protected  the second and third cochlear turns, and such 
fact did not happen in the first turn. Only the first row 
of the second turn and the third row of the third turn 
showed significantly lower values of hair cell lesion in 
the groups which received cytoprotection and there was 
no significant difference in the protective response of the 
outer hair cells with increase in the amifostine dose from 
100mg to 200mg/kg.
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